Literature DB >> 23042585

Cognitive and behavioral aspects of Smith-Lemli-Opitz syndrome.

Andrea Diaz-Stransky1, Elaine Tierney.   

Abstract

The brain's high concentrations of cholesterol make it especially vulnerable to the cholesterol biosynthetic defect that characterizes Smith-Lemli-Opitz syndrome (SLOS). An attempt to characterize the cognitive and behavioral phenotype of SLOS has identified increased rates of intellectual disability, language and motor developmental delay, repeated self-injury behaviors, sensory hyperreactivity, hyperactivity, affect dysregulation, and sleep disturbances. Some research has suggested that carriers of the gene mutation that results in SLOS display increased risk of suicidal behavior. Cholesterol dysregulation impairs neuroplasticity, which may be a mechanism underlying some of the mentioned abnormalities. Discrete positive effects have been reported with the use of cholesterol supplementation in the treatment of SLOS. Research has been limited by the small number of subjects available, and a limited understanding of lipid metabolism in the brain. Hopefully future research will help clarify the role that cholesterol plays in cognitive and behavioral abnormalities like the ones associated with SLOS. This would accelerate the development of treatments for SLOS, and perhaps also further understanding of non-syndromic psychiatric disorders such as autism and attention deficit hyperactivity disorder.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23042585     DOI: 10.1002/ajmg.c.31342

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  9 in total

1.  A Pilot Study of the Association of Markers of Cholesterol Synthesis with Disturbed Sleep in Smith-Lemli-Opitz Syndrome.

Authors:  Kurt A Freeman; Erin Olufs; Megan Tudor; Jean-Baptiste Roullet; Robert D Steiner
Journal:  J Dev Behav Pediatr       Date:  2016-06       Impact factor: 2.225

2.  Disorders of cholesterol metabolism and their unanticipated convergent mechanisms of disease.

Authors:  Frances M Platt; Christopher Wassif; Alexandria Colaco; Andrea Dardis; Emyr Lloyd-Evans; Bruno Bembi; Forbes D Porter
Journal:  Annu Rev Genomics Hum Genet       Date:  2014       Impact factor: 8.929

3.  The Brain in Oral Clefting: A Systematic Review With Meta-Analyses.

Authors:  Kinga A Sándor-Bajusz; Asaad Sadi; Eszter Varga; Györgyi Csábi; Georgios N Antonoglou; Szimonetta Lohner
Journal:  Front Neuroanat       Date:  2022-06-10       Impact factor: 3.543

Review 4.  Cholesterol in brain disease: sometimes determinant and frequently implicated.

Authors:  Mauricio G Martín; Frank Pfrieger; Carlos G Dotti
Journal:  EMBO Rep       Date:  2014-09-15       Impact factor: 8.807

5.  Pathogenesis, Epidemiology, Diagnosis and Clinical Aspects of Smith-Lemli-Opitz Syndrome.

Authors:  Simona E Bianconi; Joanna L Cross; Christopher A Wassif; Forbes D Porter
Journal:  Expert Opin Orphan Drugs       Date:  2015-03       Impact factor: 0.694

6.  Biochemical and Clinical Effects of Vitamin E Supplementation in Hungarian Smith-Lemli-Opitz Syndrome Patients.

Authors:  Katalin Koczok; László Horváth; Zeljka Korade; Zoltán András Mezei; Gabriella P Szabó; Ned A Porter; Eszter Kovács; Károly Mirnics; István Balogh
Journal:  Biomolecules       Date:  2021-08-17

Review 7.  An "Omic" Overview of Fragile X Syndrome.

Authors:  Olivier Dionne; François Corbin
Journal:  Biology (Basel)       Date:  2021-05-13

8.  Lipid rafts: a signaling platform linking cholesterol metabolism to synaptic deficits in autism spectrum disorders.

Authors:  Hansen Wang
Journal:  Front Behav Neurosci       Date:  2014-03-27       Impact factor: 3.558

9.  Smith-Lemli-Opitz-syndrome: How different is the anesthetic technique?

Authors:  Srinivasa Raghavan Govindarajan; Puneet Khanna; Amar P Bhalla; Anil Kumar
Journal:  Saudi J Anaesth       Date:  2014-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.